<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34445680</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>16</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3&#x3b2; as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8975</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22168975</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is the most common degenerative motor neuron disease in adults. About 97% of ALS patients present TDP-43 aggregates with post-translational modifications, such as hyperphosphorylation, in the cytoplasm of affected cells. GSK-3&#x3b2; is one of the protein kinases involved in TDP-43 phosphorylation. Up-regulation of its expression and activity is reported on spinal cord and cortex tissues of ALS patients. Here, we propose the repurposing of Tideglusib, an in-house non-ATP competitive GSK-3&#x3b2; inhibitor that is currently in clinical trials for autism and myotonic dystrophy, as a promising therapeutic strategy for ALS. With this aim we have evaluated the efficacy of Tideglusib in different experimental ALS models both in vitro and in vivo. Moreover, we observed that GSK-3&#x3b2; activity is increased in lymphoblasts from sporadic ALS patients, with a simultaneous increase in TDP-43 phosphorylation and cytosolic TDP-43 accumulation. Treatment with Tideglusib decreased not only phospho-TDP-43 levels but also recovered its nuclear localization in ALS lymphoblasts and in a human TDP-43 neuroblastoma model. Additionally, we found that chronic oral treatment with Tideglusib is able to reduce the increased TDP-43 phosphorylation in the spinal cord of Prp-hTDP-43<sup>A315T</sup> mouse model. Therefore, we consider Tideglusib as a promising drug candidate for ALS, being proposed to start a clinical trial phase II by the end of the year.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez-Gonz&#xe1;lez</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4593-4889</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, CSIC, Calle Ramiro Ma&#xe9;tzu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalo-Consuegra</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n en Neuroqu&#x3af;mica, Departamento de Bioqu&#x3af;mica y Biolog&#x3af;a Molecular, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Almer&#xed;a</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n en Neuroqu&#x3af;mica, Departamento de Bioqu&#x3af;mica y Biolog&#x3af;a Molecular, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Gracia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, CSIC, Calle Ramiro Ma&#xe9;tzu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lago</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n en Neuroqu&#x3af;mica, Departamento de Bioqu&#x3af;mica y Biolog&#x3af;a Molecular, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Requero</LastName><ForeName>&#xc1;ngeles</ForeName><Initials>&#xc1;</Initials><Identifier Source="ORCID">0000-0002-3416-9440</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, CSIC, Calle Ramiro Ma&#xe9;tzu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2707-8110</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, CSIC, Calle Ramiro Ma&#xe9;tzu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>B2017/BMD3813 ELA-Madrid</GrantID><Agency>Consejer&#xed;a de Educaci&#xf3;n, Juventud y Deporte, Comunidad de Madrid</Agency><Country/></Grant><Grant><GrantID>CIBERNED CB18/05/00040</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>CIBERNED CB06/05/0089</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>RTI2018-096100-B-I00</GrantID><Agency>Agencia Estatal de Investigaci&#xf3;n</Agency><Country/></Grant><Grant><GrantID>PID2019-105600RB-I00</GrantID><Agency>Agencia Estatal de Investigaci&#xf3;n</Agency><Country/></Grant><Grant><GrantID>RTI2018-0988885-B-I00</GrantID><Agency>Agencia Estatal de Investigaci&#xf3;n</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013830">Thiadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q747Y6TT42</RegistryNumber><NameOfSubstance UI="C520571">tideglusib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013830" MajorTopicYN="N">Thiadiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">GSK-3&#x3b2;</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">Tideglusib</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34445680</ArticleId><ArticleId IdType="pmc">PMC8396476</ArticleId><ArticleId IdType="doi">10.3390/ijms22168975</ArticleId><ArticleId IdType="pii">ijms22168975</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scotter E.L., Chen H.J., Shaw C.E. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics. 2015;12:352&#x2013;363. doi: 10.1007/s13311-015-0338-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0338-x</ArticleId><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.C., Sun E., Wancewicz E., Mazur C., et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011;14:459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V., Tosat-Bitrian C., Nozal V., Nagaraj S., Martin-Requero A., Martinez A. TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chem. Neurosci. 2019;10:1183&#x2013;1196. doi: 10.1021/acschemneuro.9b00026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00026</ArticleId><ArticleId IdType="pubmed">30785719</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Kwong L.K., Lee E.B., Kremmer E., Flatley A., Xu Y., Forman M.S., Troost D., Kretzschmar H.A., Trojanowski J.Q., et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Neukomm L.J., Brown R.H., Jr., Freeman M.R. Age-Dependent TDP-43-Mediated Motor Neuron Degeneration Requires GSK3, hat-trick, and xmas-2. Curr. Biol. 2015;25:2130&#x2013;2136. doi: 10.1016/j.cub.2015.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2015.06.045</ArticleId><ArticleId IdType="pmc">PMC4546534</ArticleId><ArticleId IdType="pubmed">26234214</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002;22:373&#x2013;384. doi: 10.1002/med.10011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.10011</ArticleId><ArticleId IdType="pubmed">12111750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J.H., Zhang H., Wagey R., Krieger C., Pelech S.L. Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J. Neurochem. 2003;85:432&#x2013;442. doi: 10.1046/j.1471-4159.2003.01670.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01670.x</ArticleId><ArticleId IdType="pubmed">12675919</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W., Leystra-Lantz C., Strong M.J. Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci) Brain Res. 2008;1196:131&#x2013;139. doi: 10.1016/j.brainres.2007.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.12.031</ArticleId><ArticleId IdType="pubmed">18221734</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H.J., Cha S.J., Lee J.W., Kim H.J., Kim K. Recent Advances on the Role of GSK3beta in the Pathogenesis of Amyotrophic Lateral Sclerosis. Brain Sci. 2020;10:675. doi: 10.3390/brainsci10100675.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10100675</ArticleId><ArticleId IdType="pmc">PMC7600609</ArticleId><ArticleId IdType="pubmed">32993098</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihira T., Suzuki A., Kondo T., Wakayama I., Yoshida S., Hasegawa K., Garruto R.M. Immunohistochemical expression of IGF-I and GSK in the spinal cord of Kii and Guamanian ALS patients. Neuropathology. 2009;29:548&#x2013;558. doi: 10.1111/j.1440-1789.2009.01010.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01010.x</ArticleId><ArticleId IdType="pubmed">19323791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Mu&#xf1;oz M.I., Rodr&#xed;guez-Mahillo A., Gil C., Mor&#xe1;n Y., Moneo I., Mart&#xed;nez A., Mora J.S. Glycogen Synthase Kinase-3&#x3b2; Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. JAMMR. 2013;4:263&#x2013;271. doi: 10.9734/BJMMR/2014/5578.</Citation><ArticleIdList><ArticleId IdType="doi">10.9734/BJMMR/2014/5578</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled D., James J.L., Parker S.J., Lidgerwood G.E., Duncan C., Meyerowitz J., Nonaka T., Hasegawa M., Kanninen K.M., Grubman A., et al. Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress. PLoS ONE. 2013;8:e67433. doi: 10.1371/journal.pone.0067433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067433</ArticleId><ArticleId IdType="pmc">PMC3694067</ArticleId><ArticleId IdType="pubmed">23840699</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y.M., Gupta S.K., Kim K.J., Powers B.E., Cerqueira A., Wainger B.J., Ngo H.D., Rosowski K.A., Schein P.A., Ackeifi C.A., et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013;12:713&#x2013;726. doi: 10.1016/j.stem.2013.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.04.003</ArticleId><ArticleId IdType="pmc">PMC3707511</ArticleId><ArticleId IdType="pubmed">23602540</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R., De Vos K.J., Paillusson S., Mueller S., Sancho R.M., Lau K.F., Vizcay-Barrena G., Lin W.L., Xu Y.F., Lewis J., et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat. Commun. 2014;5:3996. doi: 10.1038/ncomms4996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4996</ArticleId><ArticleId IdType="pmc">PMC4046113</ArticleId><ArticleId IdType="pubmed">24893131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambegaokar S.S., Jackson G.R. Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum. Mol. Genet. 2011;20:4947&#x2013;4977. doi: 10.1093/hmg/ddr432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr432</ArticleId><ArticleId IdType="pmc">PMC3221533</ArticleId><ArticleId IdType="pubmed">21949350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J.H., Chernoff K., Pelech S., Krieger C. Protein kinase and protein phosphatase expression in the central nervous system of G93A mSOD over-expressing mice. J. Neurochem. 2003;85:422&#x2013;431. doi: 10.1046/j.1471-4159.2003.01669.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01669.x</ArticleId><ArticleId IdType="pubmed">12675918</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh S.H., Kim Y., Kim H.Y., Hwang S., Lee C.H., Kim S.H. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp. Neurol. 2007;205:336&#x2013;346. doi: 10.1016/j.expneurol.2007.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.03.004</ArticleId><ArticleId IdType="pubmed">17433298</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munck E., Munoz-Saez E., Miguel B.G., Solas M.T., Martinez A., Arahuetes R.M. Morphometric and neurochemical alterations found in l-BMAA treated rats. Environ. Toxicol. Pharmacol. 2015;39:1232&#x2013;1245. doi: 10.1016/j.etap.2015.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etap.2015.04.022</ArticleId><ArticleId IdType="pubmed">26002186</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munck E., Munoz-Saez E., Miguel B.G., Solas M.T., Ojeda I., Martinez A., Gil C., Arahuetes R.M. beta-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): The first step towards an experimental model for sporadic ALS. Environ. Toxicol. Pharmacol. 2013;36:243&#x2013;255. doi: 10.1016/j.etap.2013.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.etap.2013.04.007</ArticleId><ArticleId IdType="pubmed">23688553</ArticleId></ArticleIdList></Reference><Reference><Citation>Boll M.C., Bayliss L., Vargas-Canas S., Burgos J., Montes S., Penaloza-Solano G., Rios C., Alcaraz-Zubeldia M. Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 2014;340:103&#x2013;108. doi: 10.1016/j.jns.2014.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.03.005</ArticleId><ArticleId IdType="pubmed">24667005</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Garcia J.A., Luna-Medina R., Alonso-Gil S., Sanz-Sancristobal M., Palomo V., Gil C., Santos A., Martinez A., Perez-Castillo A. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem. Neurosci. 2012;3:963&#x2013;971. doi: 10.1021/cn300110c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn300110c</ArticleId><ArticleId IdType="pmc">PMC3503340</ArticleId><ArticleId IdType="pubmed">23173075</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna-Medina R., Cortes-Canteli M., Sanchez-Galiano S., Morales-Garcia J.A., Martinez A., Santos A., Perez-Castillo A. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders. J. Neurosci. 2007;27:5766&#x2013;5776. doi: 10.1523/JNEUROSCI.1004-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1004-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672766</ArticleId><ArticleId IdType="pubmed">17522320</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S., Boada M., Dubois B., Hull M., Rinne J.O., Huppertz H.J., Calero M., Andres M.V., Gomez-Carrillo B., Leon T., et al. A phase II trial of tideglusib in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2015;45:75&#x2013;88. doi: 10.3233/JAD-141959.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-141959</ArticleId><ArticleId IdType="pubmed">25537011</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa E., Litvan I., Hoglinger G.U., Burn D., Lees A., Andres M.V., Gomez-Carrillo B., Leon T., Del Ser T., Investigators T. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 2014;29:470&#x2013;478. doi: 10.1002/mds.25824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25824</ArticleId><ArticleId IdType="pubmed">24532007</ArticleId></ArticleIdList></Reference><Reference><Citation>Anagnostou E., Bennett T.A., Thorpe K., Nicolson R. 5.16 A Phase 2 Randomized, Placebo-Controlled Trial of Tideglusib, an Orally Administered GSK-3 Beta Inhibitor, in the Treatment of Adolescents with ASD. J. Am. Acad. Child. Adolesc. 2018;57:S232. doi: 10.1016/j.jaac.2018.09.311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaac.2018.09.311</ArticleId></ArticleIdList></Reference><Reference><Citation>Horrigan J., Gomes T.B., Snape M., Nikolenko N., McMorn A., Evans S., Yaroshinsky A., Della Pasqua O., Oosterholt S., Lochmuller H. A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1) Pediatr. Neurol. 2020;112:84&#x2013;93. doi: 10.1016/j.pediatrneurol.2020.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2020.08.001</ArticleId><ArticleId IdType="pubmed">32942085</ArticleId></ArticleIdList></Reference><Reference><Citation>Posa D., Martinez-Gonzalez L., Bartolome F., Nagaraj S., Porras G., Martinez A., Martin-Requero A. Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. Mol. Neurobiol. 2019;56:2424&#x2013;2432. doi: 10.1007/s12035-018-1249-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1249-8</ArticleId><ArticleId IdType="pubmed">30030753</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Gonzalez L., Rodriguez-Cueto C., Cabezudo D., Bartolome F., Andres-Benito P., Ferrer I., Gil C., Martin-Requero A., Fernandez-Ruiz J., Martinez A., et al. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1delta kinase inhibitor treatment. Sci. Rep. 2020;10:4449. doi: 10.1038/s41598-020-61265-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61265-y</ArticleId><ArticleId IdType="pmc">PMC7064575</ArticleId><ArticleId IdType="pubmed">32157143</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y., Katsuno M., Takagi S., Ishigaki S., Niwa J., Hasegawa M., Tanaka F., Sobue G. Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol. Dis. 2012;45:862&#x2013;870. doi: 10.1016/j.nbd.2011.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.002</ArticleId><ArticleId IdType="pubmed">22198567</ArticleId></ArticleIdList></Reference><Reference><Citation>Alquezar C., Salado I.G., de la Encarnacion A., Perez D.I., Moreno F., Gil C., de Munain A.L., Martinez A., Martin-Requero A. Targeting TDP-43 phosphorylation by Casein Kinase-1delta inhibitors: A novel strategy for the treatment of frontotemporal dementia. Mol. Neurodegener. 2016;11:36. doi: 10.1186/s13024-016-0102-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0102-7</ArticleId><ArticleId IdType="pmc">PMC4852436</ArticleId><ArticleId IdType="pubmed">27138926</ArticleId></ArticleIdList></Reference><Reference><Citation>McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Abrams S.L., Montalto G., D&#x2019;Assoro A.B., Libra M., Nicoletti F., Maestro R., et al. Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: Opportunities for therapeutic intervention. Leukemia. 2014;28:15&#x2013;33. doi: 10.1038/leu.2013.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2013.184</ArticleId><ArticleId IdType="pmc">PMC3887408</ArticleId><ArticleId IdType="pubmed">23778311</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C., Xiao G., Hu J. Regulation of Wnt/beta-catenin signaling by posttranslational modifications. Cell. Biosci. 2014;4:13. doi: 10.1186/2045-3701-4-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2045-3701-4-13</ArticleId><ArticleId IdType="pmc">PMC3977945</ArticleId><ArticleId IdType="pubmed">24594309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>del Ser T., Steinwachs K.C., Gertz H.J., Andres M.V., Gomez-Carrillo B., Medina M., Vericat J.A., Redondo P., Fleet D., Leon T. Treatment of Alzheimer&#x2019;s disease with the GSK-3 inhibitor tideglusib: A pilot study. J. Alzheimers Dis. 2013;33:205&#x2013;215. doi: 10.3233/JAD-2012-120805.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120805</ArticleId><ArticleId IdType="pubmed">22936007</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaca G., Martinez-Gonzalez L., Fernandez A., Rojas-Prats E., Porras G., Cuevas E.P., Gil C., Martinez A., Martin-Requero A. Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) J. Neurochem. 2021;156:379&#x2013;390. doi: 10.1111/jnc.15118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15118</ArticleId><ArticleId IdType="pubmed">32628315</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J., Van Broeckhoven C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum. Mol. Genet. 2013;22:R77&#x2013;R87. doi: 10.1093/hmg/ddt349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt349</ArticleId><ArticleId IdType="pmc">PMC3782069</ArticleId><ArticleId IdType="pubmed">23900071</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F., Lee V.M., Trojanowski J.Q. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP-43 proteinopathies. Neuropathology. 2010;30:103&#x2013;112. doi: 10.1111/j.1440-1789.2009.01091.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01091.x</ArticleId><ArticleId IdType="pmc">PMC3131978</ArticleId><ArticleId IdType="pubmed">20102519</ArticleId></ArticleIdList></Reference><Reference><Citation>Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Pt 1Biochem. J. 2001;359:1&#x2013;16. doi: 10.1042/bj3590001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3590001</ArticleId><ArticleId IdType="pmc">PMC1222116</ArticleId><ArticleId IdType="pubmed">11563964</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V., Perez D.I., Roca C., Anderson C., Rodriguez-Muela N., Perez C., Morales-Garcia J.A., Reyes J.A., Campillo N.E., Perez-Castillo A.M., et al. Subtly Modulating Glycogen Synthase Kinase 3 beta: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. J. Med. Chem. 2017;60:4983&#x2013;5001. doi: 10.1021/acs.jmedchem.7b00395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b00395</ArticleId><ArticleId IdType="pubmed">28548834</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F., Al-Chalabi A., Filippi M., Hardiman O., Kaji R., Meininger V., Nakano I., Shaw P., Shefner J., van den Berg L.H., et al. The El Escorial criteria: Strengths and weaknesses. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2015;16:1&#x2013;7. doi: 10.3109/21678421.2014.964258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.964258</ArticleId><ArticleId IdType="pubmed">25482030</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinen P. Human peripheral blood and bone marrow cell separation using density gradient centrifugation on Lymphoprep and Percoll in haematological diseases. Scand. J. Clin. Lab. Invest. 1987;47:709&#x2013;714. doi: 10.3109/00365518709168934.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365518709168934</ArticleId><ArticleId IdType="pubmed">3685871</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D.M. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol. Biol. 1998;79:179&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">9463833</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan K.S., Halang L., Woods I., Prehn J.H. A high-fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43A315T mutant C57BL6/J mice. Dis. Model. Mech. 2016;9:1029&#x2013;1037. doi: 10.1242/dmm.024786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.024786</ArticleId><ArticleId IdType="pmc">PMC5047697</ArticleId><ArticleId IdType="pubmed">27491077</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>